Latest filing published 17 Sept 2026 for CG Oncology, Inc., €520. Read the official filing
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
Leonard e. Post (board member) discloses dealings in 3 companies, chiefly CG Oncology, Inc., uniQure N.V. and Fulgent Genetics, Inc. We count 35 filings; the first trade dates from 24 February 2022 and the latest from 15 September 2026.
Every open-market trade on record is a sale: 10 sales worth €293k. The amount is not disclosed for 2 filings. The rest of the record consists of 6 share grants and 19 option exercises. 2026 to date brings no purchases and 6 sales.
On 17 September 2026 came the latest disclosure, an option exercise for €520 in CG Oncology, Inc. Filings reach the SEC (Form 4) feed a median of 2 days after the trade. Section 16 rules allow two business days to file each Form 4. Keep in mind that insiders sell for many reasons unrelated to the outlook, from tax bills to estate planning. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
25 of 35 declarations